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Self-expanding metal stent placement and single-dose brachytherapy are commonly used for the palliation of oesophageal
obstruction due to inoperable oesophagogastric cancer. We randomised 209 patients to the placement of an Ultraflex stent
(n¼108) or single-dose brachytherapy (12Gy, n¼101). Cost comparisons included comprehensive data of hospital costs, diagnostic
interventions and extramural care. We acquired detailed information on health care consumption from a case record form and from
monthly home visits by a specialised nurse. The initial costs of stent placement were higher than the costs of brachytherapy (h1500 vs
h570; Po0.001). Total medical costs were, however, similar (stent h11195 vs brachytherapy h10078, P40.20). Total hospital stay
during follow-up was 11.5 days after stent placement vs 12.4 days after brachytherapy, which was responsible for the high intramural
costs in both treatment groups (stent h6512 vs brachytherapy h7982, P40.20). Costs for medical procedures during follow-up were
higher after stent placement (stent h249 vs brachytherapy h168, P¼0.002), while the costs of extramural care were similar (h1278 vs
h1046, P40.20). In conclusion, there are only small differences between the total medical costs of both palliative treatment
modalities, despite the fact that the initial costs of stent placement are much higher than those of brachytherapy. Therefore, cost
considerations should not play an important role in decision making on the appropriate palliative treatment strategy for patients with
malignant dysphagia.
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The incidence of oesophageal cancer has risen rapidly, due to a
marked increase in the incidence of adenocarcinoma (Devesa et al,
1998; Botterweck et al, 2000). Oesophageal cancer is a disease with
a high mortality, as reflected by a 5-year survival of 10–15%
(Pisani et al, 1999). Moreover, more than 50% of patients with
oesophageal cancer have already inoperable disease at presenta-
tion. Most of these patients require palliative treatment to relieve
progressive dysphagia (Sagar et al, 1994). Treatment options
presently available for palliation of dysphagia include self-
expanding metal stent placement (Kozarek et al, 1996; Bartelsman
et al, 2000; Siersema et al, 2001), laser therapy (Dallal et al, 2001),
photodynamic therapy (PDT) (Luketich et al, 2000; Moghissi et al,
2000), external beam radiation in combination with brachytherapy
(Taal et al, 1996; Schraube et al, 1997), brachytherapy as a sole
treatment (Jager et al, 1995; Sur et al, 2002; Homs et al, 2003a) and
dilatation (Lundell et al, 1989). A disadvantage of laser therapy is
that repeated treatment sessions are required to achieve and
maintain adequate palliation (Dallal et al, 2001; Spencer et al,
2002). A combined treatment of external beam radiation with
brachytherapy is often too intensive for patients with inoperable
disease due to metastases or a poor medical condition. Photo-
dynamic therapy involves the local destruction of tumour tissue by
light of a specific wavelength activating a previously administered
photosensitiser, which is retained in malignant tissue. Due to the
high costs of the treatment, the side effects and the necessity of
repeated treatments every 6–8 weeks, PDT is not considered to be
the most optimal treatment for palliation of malignant dysphagia
(Lightdale et al, 1995). Dilatation can relieve dysphagia tempora-
rily, but it often provides relief palliation for a short period. In
many patients with inoperable disease, a stent is placed for the
palliation of dysphagia. In addition, brachytherapy as a sole
treatment is frequently used in Western Europe, South Africa,
Japan and to a lesser extent in the USA. Both stent placement and
brachytherapy have been proven to be effective in relieving
dysphagia with a low complication rate, but recurrent dysphagia
due to various causes is seen in 30–40% of patients (Brewster et al,
1995; Kozarek et al, 1996; Bartelsman et al, 2000; Siersema et al,
2001; Sur et al, 2002; Homs et al, 2003a).
In order to comprehensively assess the relative merits of the
different palliative treatments of malignant dysphagia, health
economic aspects should be incorporated. Remarkably, the
economic implications of both stent placement and brachytherapy
have been evaluated only in a few studies (Adam et al, 1997;
Farndon et al, 1998; Nicholson et al, 1999; Dallal et al, 2001;
O’Donnell et al, 2002). If costs were considered, these were only
‘roughly’ calculated (Dallal et al, 2001), using charges/fees and with
little information about the differentiation of the costs. In addition,
the number of patients incorporated in the studies was low
(Farndon et al, 1998; Dallal et al, 2001; O’Donnell et al, 2002). In
studies on costs, this may result in a high degree of distortion,
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lbecause peaks in volumes of some expensive cost items can highly
influence the average outcomes.
We aimed to study the total direct and indirect costs of
brachytherapy and stent placement in the palliation of malignant
dysphagia within the framework of a randomised trial. We present
estimates of the full cost price, based on real resource use, in
substantial patient groups.
MATERIALS AND METHODS
Study population
We performed a prospective study in three university hospitals
and six general hospitals in the Netherlands. Between December
1999 and July 2002, 209 consecutive patients with dysphagia from
inoperable carcinoma of the oesophagus or gastric cardia due to
metastases and/or a poor medical condition were randomised to
placement of a covered Ultraflex stent (n¼108) or single-dose
(12Gy) brachytherapy (n¼101). For brachytherapy, a flexible
applicator (Bonvoisin-Ge ´rard Esophageal Applicator, Nucletron,
Veenendaal, The Netherlands) with a diameter of 10mm was
passed down the oesophagus. A single dose of 12Gy was
administered with the radioactive source
192Iridium at 1cm from
the source axis of the applicator. The study was approved by the
Central Committee on Research Involving Human Subjects in the
Netherlands.
Study end points
The clinical outcomes were functional outcome, complications,
persisting or recurrent dysphagia needing re-intervention, survival
and quality of life, as measured by standardised questionnaires.
The clinical outcomes have been presented in detail elsewhere
(Homs et al, 2003b,c). Here, we will focus on the real medical costs
of the two treatment strategies. Costs were studied from a societal
perspective and were estimated for the period after randomisation
until death for 95% of the patients, or a follow-up of at least 9
months for the remaining 5% of patients.
Follow-up
Patients were prospectively followed by home visits of specially
trained research nurses at 14 days, 1 month and then monthly until
1 year after treatment. After 1 year, patients were visited every 3
months, and/or telephone calls to the patient and/or the patients’
general practitioner were made. For each patient, we registered the
number of inpatient days, the time needed for nursing care and
therapy as well as the visits to physicians and other health
practitioners by a checklist filled in by the research nurse. The
response was more than 90% during the entire follow-up period.
The participating clinicians filled out standardised case record
forms (CRFs) during control visits, re-treatments and admissions.
Cost calculations
Real medical costs were calculated by multiplying the volumes of
health care use with the corresponding unit prices. We made a
distinction between the full cost price of the interventions of
brachytherapy and stent placement by itself and the total medical
costs per patient during follow-up.
The calculation of the full cost price of brachytherapy and stent
placement consisted of detailed measurement of investments in
manpower, equipment, materials, housing and overhead. The
salary schemes of hospitals and other health care suppliers were
used to estimate costs per hour for each caregiver. Taxes, social
securities and vacations were included, as well as the costs of the
time that could not be assigned to other patients. The costs of
equipment included those of depreciation, interest and main-
tenance.
For the calculation of the total medical costs per patient, we
distinguished intramural medical costs (inpatient days, health
practitioner activities, the full cost price of the medical treatment
and other medical procedures) and extramural medical costs
(home care, general practitioner). Costs caused by loss of
production due to absence from work were not taken into
account, because the majority of patients were retired from work.
For the most important cost items, unit prices were determined
by following the micro-costing method (Gold et al, 1996), which is
based on a detailed inventory and measurement of all resources
used. For instance, we registered the time investments of health
practitioners per patient (during the intervention). Costs for
inpatient days in hospital were estimated as real, basic costs per
day using detailed information from the financial department of
the hospital. We made a distinction between the costs of general
and university hospitals. These estimates included overhead and
indirect costs. From a differential point of view, that is,
comparison of the two treatment strategies, some diagnostic
interventions were decided to be less relevant. We chose not to
invest much time and effort in exploring costs that were unlikely to
make any difference to the study result (Drummond et al, 1997),
for example, because they were low in price or volume. For these
items, we used charges as a proxy of real costs. In the Netherlands,
a detailed ‘fee for service’ system is used for the remuneration of
medical interventions and diagnostic procedures. In order to
calculate the costs for medication, we used average charges for
analgesics, antibiotics and additional medications.
Table A1 (Appendix A) gives an overview of the cost categories
and data used in the cost calculations. We reported the costs in
Euro for the year 2002, when 1 Euro equalised approximately 1 US
dollar. Discounting was not relevant because of the limited time
horizon (median survival 4–5 months).
Statistical analysis
All analyses were performed on an intention-to-treat basis. The
cost differences between brachytherapy and stent placement were
analysed using the Mann–Whitney U test. Since cost data per
patient (but not per day care) are typically highly skewed, we used
nonparametric bootstrap techniques to derive a 95% confidence
interval for the differences in distributions of the direct medical
costs.
In a sensitivity analysis, the effect of excluding ‘palliation-related
costs’ was assessed by leaving these costs out of consideration. We
performed calculations assuming that nursing home admissions
and nursing care at home were not directly related to both
treatments, but could be attributed to the advanced stage of the
disease.
RESULTS
Patient characteristics and clinical outcomes
The two patient groups were comparable with respect to patient
and tumour characteristics. Both treatment groups consisted
predominantly of males, with a mean age of 69 years (Table 1).
Dysphagia improved more rapidly after stent placement than
after brachytherapy. However, the overall improvement of
dysphagia was better after brachytherapy. More complications
occurred after stent placement (33% total complications vs 21%
after brachytherapy; P¼0.02). Major complications within 7 days
after treatment included perforation (n¼3), fever (n¼2), severe
pain (n¼2) and aspiration pneumonia (n¼2). Late major
complications consisted predominantly of haemorrhage (n¼19)
occurring more frequently after stent placement (14 vs 5 after
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recurrent dysphagia was not significantly different for both groups
(40 vs 43%, respectively). Recurrent dysphagia after stent
placement was predominantly caused by tumour overgrowth
(n¼16), stent migration (n¼18) or food bolus obstruction
(n¼16), and was treated by placement of a second stent,
endoscopic stent clearance or a variety of other treatments. The
majority of re-interventions after brachytherapy were caused by
tumour persistence (n¼18) or tumour recurrence (n¼26), both
most frequently treated with placement of a stent.
The median survival was similar for both treatment groups
(stent 145 vs brachytherapy 155 days). There was an overall long-
term benefit in general (EORTC QLQ C-30 and EuroQol-5D) and
disease-specific quality of life scores (EORTC OES-23) in the
brachytherapy group during follow-up.
Costs
The initial cost price of treatment, based on real resource use, was
much higher for stent placement (h1500) than for brachytherapy
(h570). The main cause for this difference was the high purchase
costs of the Ultraflex stent (h1100) (Table 2).
Table 3 gives an overview of the average health care use and
costs per patient for stent placement and brachytherapy. Patients
randomised to brachytherapy were admitted on average 7.1 days
longer in a health care institution than patients randomised to
stent placement (23.4 vs 16.3 days). The main reason for this was
the longer period patients randomised to brachytherapy were
admitted to nursing homes (11.0 vs 4.6 days). The average time
spent in hospital was similar for both treatments (12.4 for
brachytherapy and 11.5 for stent placement). The costs for
intramural care were by far the highest cost category for both
treatments, but differences were not statistically significant (stent
placement h6512 vs brachytherapy h7982, P40.20). Costs of
medical procedures during follow-up were significantly higher for
stent placement (h249) than for brachytherapy (h168) (P¼0.002),
since major complications and re-interventions occurred more
often after stent placement than brachytherapy. The average costs
for extramural care were h1278 for brachytherapy and h1046 for
stent placement. For both treatments, this could largely be
attributed to home visits by the general practitioner and
specialised nursing care at home. The costs for medications were
similar for brachytherapy and stent placement (h350 and h325).
The total average costs per patient for both treatments were
similar at h11195 for brachytherapy and h10078 for stent
placement (P40.20). If the ‘palliation-related’ health care was
not taken into consideration, then the costs of intramural and
extramural care for brachytherapy and stent placement decreased.
This resulted in total medical costs for brachytherapy of h8490 and
for stent placement of h8538 (P40.20).
DISCUSSION
We found only small differences between the total medical costs of
single-dose brachytherapy as compared to metal stent placement
for the palliation of dysphagia from inoperable oesophageal
carcinoma. Stent placement was initially more expensive than
brachytherapy, due to the high purchase costs of the stent, but at
the long term costs were comparable.
Many patients in both treatment groups needed re-intervention
for persistent or recurrent dysphagia. Of the patients randomised
to brachytherapy, 45 out of 101 (45%) subsequently received a
stent, while 24 out of 108 (22%) of the patients randomised to stent
placement received a second stent during follow-up. Since our
analysis was based on the intention-to-treat principle, costs of
non-assigned treatment were accounted to the randomised
treatment group. Total treatment costs, which included the average
costs of additional treatment plus re-intervention, were higher for
stent placement. However, if the intramural and extramural health
care costs were also taken into account, then these high initial costs
were only a small part of the total medical costs, which resulted in
similar total medical costs.
Table 1 Characteristics of 209 patients randomised to brachytherapy or stent placement for palliation of malignant dysphagia
Brachytherapy Stent placement
Randomised 101 108
Age 69713 69711
Gender (male/female) 76/25 86/22
WHO performance score before treatment (mean7s.d.) 1.070.4 0.970.5
Indications for treatment
Metastases 66 (65%) 68 (63%)
Poor medical condition 23 (23%) 28 (26%)
Both 12 (12%) 12 (11%)
Tumour length (cm) (mean7s.d.) 7.572.6 7.572.8
Received assigned intervention 96 (brachytherapy) 105 (stent)
Re-intervention 45 (stent) 3 (second brachytherapy) 2 (brachytherapy) 24 (second stent)
Median survival (days) 155 (95% CI: 128–182) 145 (95% CI: 104–186)
Total complications 23 in 21 patients (21%) 45 in 36 patients (33%)
Major complications 14 in 13 patients (13%) 28 in 27 patients (25%)
Minor complications 8 in 8 patients (8%) 16 in 16 patients (15%)
Persistent/recurrent dysphagia 53 in 43 patients (43%) 52 in 43 patients (40%)
Table 2 Full cost price (h, 2002) of brachytherapy and stent placement
Cost category Brachytherapy Stent placement
Personnel 152 74
Equipment 75 40
Materials 14 1307
Housing/overhead 70 40
Diagnostics 259 37
Total costs 570 1500
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only on the initial costs. This would imply that stent placement,
with the high purchase costs of the device, would be less attractive
than brachytherapy. In this study, we clearly demonstrated that the
total medical costs of stent placement and brachytherapy were
similar when the full follow-up period was considered. This
illustrates that cost comparisons between interventions may vary
substantially, depending on which, and how many, components
are included in a total cost equation (Sahai, 2000).
Few studies have been published on costs of brachytherapy or
stent placement in the palliative treatment of oesophageal cancer.
Three studies compared stent placement with plastic endoprosth-
eses (O’Donnell et al, 2002), conventional therapy (Nicholson et al,
1999) or thermal ablative therapy (Dallal et al, 2001). These three
studies reported corresponding initial costs for stent placement,
but found lower total medical costs, compared to our study. Dallal
et al (2001) included only the costs of the intervention and hospital
stay in the total costs for stent placement (h4920), which can
explain the difference in total costs compared to our study. They
found a median hospital stay of 12 days after stent placement,
similar to findings in our study (Table 3). Farndon et al (1998)
compared the placement of a plastic endoprosthesis with single-
dose brachytherapy and showed that the total costs of brachyther-
apy (h2603) were lower compared to stenting (h3564). Presently,
plastic endoprostheses are no longer considered adequate for
palliation of malignant dysphagia due to a high procedure-related
complication rate with plastic endoprostheses (Siersema et al,
1998). Since there is no detailed information available on the costs
in the above-mentioned articles (Farndon et al, 1998; Nicholson
et al, 1999; Dallal et al, 2001; O’Donnell et al, 2002), it is not
possible to explain the differences in total costs between these
studies and ours. It could well be that both intramural and
extramural health care use was under-reported. Finally, the
number of patients included and receiving stent placement or
brachytherapy was relatively low (no35) in these studies (Farndon
et al, 1998; Nicholson et al, 1999; Dallal et al, 2001; O’Donnell et al,
2002).
A common problem when using clinical trials for any kind of
cost assessment arises from the fact that the clinical protocol
mandates more visits, consultations and examinations than
otherwise used in clinical practice (Myrvold et al, 2001). For a
treatment in a research setting, there will be more costs, compared
to daily practice. Therefore, we excluded protocol-driven medical
care such as visits of the nurses from our cost calculation.
The main goal of these visits was, apart from giving advice to
patients, registration of health care consumption and outcomes,
which is, of course, not common practice in normal daily care of
patients.
Table 3 Average health care use and costs (h, 2002) per patient for stent placement and brachytherapy
Brachytherapy (n¼101) Stent placement (n¼108)
95% CI
a
Cost category Cost price Volume Costs Volume Costs Mann–Whitney
Treatment
Brachytherapy 570 0.96 547 0,019 11
Stent placement 1500 0.58 870 1,29 1935
1417 1946 [253, 822] Po0.001
Intramural care
Hospital (academic) 520 7.7 4006 6.9 3587
Hospital (general) 381 4.7 1788 4.6 1760
ICU 1450 0.02 31 0.06 72
Nursing home 173 11 1898 4.8 838
Physician (academic) 135 1.41 190 1.30 176
Physician (general) 98 0.70 69 0,82 79
7982 6512 [–4341, 1104] P40.20
Medical procedures
Endoscopy 125 0.74 93 1.17 146
PEG 100 0.04 4 0.04 4
X-ray thorax 37 0.78 29 1.41 52
X-ray abdomen 37 0.07 3 0.21 5
Ultra-sound abdomen 42 0.05 3 0.04 2
X-ray oesophagus 37 0.13 5 0.19 7
ERT 39 0,81 32 0,57 22
Adjustment ERT 98 0,15 15 0,09 9
168 249 [3, 137] P¼0.002
Extramural care
General practitioner (inpatient) 19 0,9 18 1,06 20
General practitioner (home visit) 37 9 333 8,1 298
Nursing care at home (specialised) 55,6 13,4 750 11,4 638
Nursing care at home 32,4 1,9 61 2 64
Drip-feed 8,5 13,7 116 3,05 26
1278 1046 [–783, 227] P40.20
Medication 350 325
Total costs per patient 11195 10078 [–3790, 1806] P40.20
aDerived from 2000 bootstrap samples drawn with replacement.
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treatment of malignant disease and palliative therapy have
received little attention. This may be due to the inherent
difficulties in performing such studies. Follow-up of patients with
malignant disease is sometimes difficult since the mortality rate is
high, particularly among patients receiving palliative therapy
(McQuay & Moore, 1994). In a palliative setting, it is sometimes
difficult to differentiate between health care consumption, which
can be attributed to the palliative stage of the disease or only to the
treatment modality. If palliation-related costs were excluded, we
found a decrease in the total costs of both treatments, but this did
not affect the final conclusion that the total costs for brachytherapy
and stent placement were similar.
This study focused on costs and not on efficiency. The primary
aim of both treatments is to palliate symptoms rather than to
improve the survival of oesophageal cancer. Both treatments
resulted in an improvement of an important symptom of
inoperable oesophageal cancer, that is, dysphagia. As survival of
the two treatment groups was comparable, we did not perform a
formal cost-effectiveness analysis. Despite a less rapid relief of
dysphagia and a higher initial failure rate, brachytherapy was
found to be an attractive alternative to stent placement in the
palliation of malignant dysphagia, as brachytherapy was safer with
fewer procedures needed for recurrent dysphagia (Homs et al,
2003b).
In conclusion, our study provides detailed insight into the
total medical costs of two frequently used palliative treatments
of dysphagia due to oesophageal cancer, that is, stent placement
and brachytherapy. In spite of the higher initial costs for
stent placement than for brachytherapy, total medical costs were
similar. Therefore, cost considerations should not play an
important role in decision making on the appropriate treatment
strategy.
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Appendix A
The Dutch SIREC study group consisted of :
Erasmus MC/University Medical Center Rotterdam: Department
of Gastroenterology & Hepatology: Marjolein YV Homs, Peter D
Siersema, Ernst J Kuipers; Department of Public Health: Ewout W
Steyerberg, Suzanne Polinder, Marie-Louise Essink-Bot; Depart-
ment of Radiotherapy: Wilhelmina MH Eijkenboom; Department
of Surgery: Hugo W Tilanus. Academic Medical Center, Amster-
dam: Department of Radiotherapy: Lucas JA Stalpers; Department
of Gastroenterology & Hepatology: Joep FWM Bartelsman;
Department of Surgery: Jan JB van Lanschot. University Medical
Center Utrecht: Department of Radiotherapy: Harm K Wijrdeman.
Rijnstate Hospital Arnhem: Department of Gastroenterology: Chris
JJ Mulder, Peter J Wahab. Arnhem Radiotherapeutic Institute:
Janny G Reinders. Antoni v Leeuwenhoek Hospital, Amsterdam:
Department of Gastroenterology: Henk Boot; Department of
Radiotherapy Berthe MP Aleman. Leyenburg Hospital, The Hague:
Department of Gastroenterology: Jan J Nicolai; Department of
Radiotherapy: FM Gescher. Medical Center Haaglanden, The
Hague: Department of Internal Medicine: Maarten AC Meijssen;
Department of Radiotherapy: RGJ Wiggenraad. Gelre Hospital,
Apeldoorn: Department of Internal Medicine: Jitty M Smit. Reinier
de Graaf Hospital, Delft: Department of Gastroenterology: CJM
Bolwerk.
Table A1 Cost categories and data used in cost calculations
Data collection health
care use
Cost category Parameter
CRF
(physician)
Questionnaire
(nurse)
Cost estimate
(Unit price)
Treatment
Brachytherapy Number * Real costs
Stent placement Number * Real costs
Inpatient days
Hospital
(academic)
Days * * Real costs
Hospital
(general)
Days * * Real costs
ICU Days * * Real costs
Nursing home Days * Charges
Health practitioner (inpatient)
Physician
(academic)
Visits * * Real costs
Physician
(general)
Visits * * Real costs
Medical procedures
Endoscopy Number * Real costs
PEG Number * Charges
X-ray thorax Number * Charges
X-ray stomach Number * Charges
Ultra-sound scan
stomach
Number * Charges
X-ray
oesophagus
Number * Charges
ERT Number * Charges
Other therapy Number * Charges
Extramural care
General
practitioner
(inpatient)
Visits * Fees
General
practitioner (home
visit)
Visits * Fees
Nursing care at
home
Number * Charges
Nursing care at
home (specialised)
Number * Charges
Drip-feed Days * Charges
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